摘要
目的观察重组人白介素11(rhIL-11)对急性淋巴细胞白血病(ALL)患儿化疗后血小板减少的疗效和安全性。方法选取36例ALL化疗后血小板减少患儿,随机分为治疗组和对照组,治疗组患儿在化疗结束后24 h每日皮下注射rhIL-11,应用5 d;对照组不用rhIL-11。观察两组患儿血小板数值变化,记录血小板输注量及治疗组不良反应。结果治疗组较对照组血小板恢复时间短,输注血小板少,差异有统计学意义。治疗组rhIL-11不良反应轻微。结论 rhIL-11能明显提高儿童ALL化疗后血小板数量,减少血小板输注,临床应用安全,综合临床费用降低。
Objective To investigate the effects of recombinant human interleukin-11 （rhIL-11 ） treatment on thrombocytopenia in childhood acute lymphoblastic leukemia （ALL） after chemotherapy. Methods Total of 36 patients of childhood ALL suffering thrombocytopenia were randomly divided into treatment group and control group. Twenty-four hours after chemotherapy, only patients of the treatment group were given daily subcutaneous injection of rhIL-11 for 5 days. Changes of the platelet count were observed, the amount of platelet transfusion and adverse reactions were recorded. Results Compared with the control group, recovery time of platelet count was shorter, platelet transfusion was less in the treatment group, and the differences were statistically significant, while adverse reaction was mild. Conclusions Application of rhIL-11 can improve platelet count obviously after chemotherapy of ALL children, reduce platelet transfusion, and it is clinically safe and affordable
出处
《临床儿科杂志》
CAS
CSCD
北大核心
2011年第5期429-430,共2页
Journal of Clinical Pediatrics
